Banner for leaf pages 2

Bortezomib (Velcade)

Also known as Velcade

Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

Source: Wikipedia

Estimated Total Cost: $4980.08 for an average of 21 days supply

What is it prescribed for?

Patients are most commonly prescribed bortezomib to treat multiple myeloma, coronary atherosclerosis, kidney failure, and rabies.

What drug interactions are known?

Do not take bortezomib if you are taking any of the following:

Critical Interactions


Significant Interactions

Ajax-loader Loading...